TON - April 2020, Vol 13, No 2

TON April 2020, Vol 13, No 2 Cover

The Association for Value-Based Cancer Care held a webcast with healthcare experts representing major industry stakeholders to address the impact of the COVID-19 pandemic on oncology delivery systems and the management of patients with cancer. Read More ›

From The Editor TON April 2020
The April issue of The Oncology Nurse-APN/PA (TON) is filled with important news for today’s oncology nurse. Read More ›

The Oncology Nurse-APN/PA spoke with Lisa Senerchia, RN, BSN, OCN, about her roles and responsibilities at the University of Chicago Cancer Center at Silver Cross Hospital, New Lenox, IL, and how a team-based treatment approach can improve the lives of patients with cancer. Read More ›

A Call to Focus on Financial Toxicity and Quality of Life in Genitourinary Malignancies
San Francisco, CA—Delivering the keynote address at the 2020 Genitourinary Cancers Symposium, David F. Penson, MD, MPH, MMHC, Hamilton and Howd Chair in Urologic Oncology, Vanderbilt University Medical Center, Nashville, TN, highlighted the need to move toward patient-centered decisions beyond survival, focusing on patient-­centered outcomes by integrating quality of life (QOL) and financial toxicity into the shared, treatment-related, decision-making process. Read More ›

San Francisco, CA—Second-line treatment with a 3-drug regimen that included the PD-1 inhibitor nivolumab (Opdivo), the VEGF receptor antagonist ramucirumab (Cyramza), and chemotherapy with the taxane paclitaxel, showed durable and impressive response rates, regardless of PD-L1 expression, in patients with advanced gastric cancers. Read More ›

San Francisco, CA—Positron emission tomography (PET) scanning targeted to detect prostate-specific membrane antigen (PSMA) is poised to overtake conventional imaging, according to presentations at the 2020 Genitourinary Cancers Symposium. Read More ›

Cabozantinib-Atezolizumab Combination Shows Activity in Difficult-to-Treat Prostate Cancer
San Francisco, CA—Combining cabozantinib (Cabometyx) with atezolizumab (Tecentriq) induced responses in 32% of patients with metastatic castration-resistant prostate cancer (CRPC) who had soft-tissue progression after previous novel hormonal therapy. Read More ›

Combination of NUC-1031 plus Cisplatin Shows Promise as First-Line Treatment for Advanced Biliary Tract Cancer
San Francisco, CA—Cholangiocarcinoma (CCA), a type of biliary tract cancer, is a rare malignancy, with no FDA-approved medications specifically for this type of cancer. The current standard first-line treatment for patients with locally advanced or metastatic CCA is a chemotherapy combination of gemcitabine and cisplatin. Read More ›

San Francisco, CA—Although there is a biological rationale that supports the “abscopal” effects of radiation therapy plus checkpoint immunotherapy in fighting cancer, this combination showed mixed results and no robust effects in patients with metastatic renal-cell carcinoma (RCC), according to results of 2 preliminary studies presented at the 2020 Genitourinary Cancers Symposium. Read More ›

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: